Results 41 to 50 of about 13,380 (189)

Eculizumab in atypical hemolytic uremic syndrome: long-term clinical course and histological findings [PDF]

, 2011
Atypical hemolytic uremic syndrome (aHUS) is a thrombotic microangiopathy associated with defective regulation of the alternative complement pathway.
Sibylle Tschumi, Tschumi, Sibylle, Simonetti, Giacomo D, Giacomo D. Simonetti, Magdalena Riedl, Barbara S. Bucher, Bucher, Barbara S, Gugger, Mathias, Riedl, Magdalena, Mathias Gugger, Tschumi S, Gugger M, Riedl M, Simonetti GD, Bucher BS   +14 more
core   +2 more sources

Data_Sheet_2_Utilization Pattern for Eculizumab Among Children With Hemolytic Uremic Syndrome.PDF

, 2021
Background: Hemolytic uremic syndrome (HUS) is a complex disease with multi-organ involvement. Eculizumab therapy is recommended for treatment of complement mediated hemolytic uremic syndrome (cHUS).
Rachel Millner (11522578), Parthak Prodhan (11522584), Richard Blaszak (11522575), Saritha Ranabothu (11522572), Clare C. Brown (9509210), Kristen Rice Moore (11522581)   +5 more
core   +1 more source

Beyond Nature's Blueprint: Macrocyclic Peptides Containing Unnatural Amino Acids in Therapeutic Development

Angewandte Chemie, EarlyView.
Strategic incorporation of unnatural amino acids transforms macrocyclic peptides into drug‐like molecules capable of engaging challenging targets. These building blocks enhance stability, permeability, and bioavailability, accelerating the development of next‐generation peptide therapeutics.
Krishna K. Sharma, Komal Sharma, Anku Sharma, Kamya Rao, Rahul Jain, Brett VanVeller   +5 more
wiley   +2 more sources

Case report: Short-term eculizumab use in atypical HUS associated with Lemierre's syndrome and post-infectious glomerulonephritis

Frontiers in Medicine, 2023
Atypical hemolytic uremic syndrome (aHUS) is a rare disease caused by genetic abnormalities, infections, autoimmune diseases, drugs, and malignancies.
Sanober Sadiq, Anatoly Urisman, Onur Cil
doaj   +1 more source

Eculizumab as an emergency treatment for adult patients with severe COVID-19 in the intensive care unit: A proof-of-concept study

EClinicalMedicine, 2020
Background: Complement pathway inhibition may provide benefit for severe acute respiratory illnesses caused by viral infections such as COVID-19. We present results from a nonrandomized proof-of-concept study of complement C5 inhibitor eculizumab for ...
Djillali Annane, Nicholas Heming, Lamiae Grimaldi-Bensouda, Véronique Frémeaux-Bacchi, Marie Vigan, Anne-Laure Roux, Armance Marchal, Hugues Michelon, Martin Rottman, Pierre Moine   +9 more
doaj   +1 more source

Use of Eculizumab in Pediatric Patients With Transplant Associated Thrombotic Microangiopathy

Frontiers in Pediatrics, 2021
Background: Transplant-associated thrombotic microangiopathy (TA-TMA) is a serious complication of hematopoietic stem cell transplantation (HSCT) associated with high morbidity and mortality. High-risk TA-TMA (hrTA-TMA) is characterized by multifactorial
Laura Gomez-Ganda, Maria Isabel Benitez-Carabante, Aurora Fernandez-Polo, Marina Muñoz-Lopez, Berta Renedo-Miro, Gema Ariceta, Cristina Diaz De Heredia   +6 more
doaj   +1 more source

Inebilizumab in AQP4‐Seropositive NMOSD: One‐Year Follow‐Up From a Multicenter, Real‐World Study

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Real‐world evidence on inebilizumab among neuromyelitis optica spectrum disorder (NMOSD) patients is lacking. This study assessed inebilizumab among Chinese patients with aquaporin 4 autoantibody (AQP4‐IgG)‐seropositive NMOSD in a real‐world setting.
Mengcui Gui, Jiayang Zhan, Wei Li, Tao Jin, Dan He, Daishi Tian, Zhijun Li, Jing Lin, Yue Li, Hongyu Zhou, Bitao Bu   +10 more
wiley   +1 more source

Data_Sheet_1_Utilization Pattern for Eculizumab Among Children With Hemolytic Uremic Syndrome.PDF

, 2021
Background: Hemolytic uremic syndrome (HUS) is a complex disease with multi-organ involvement. Eculizumab therapy is recommended for treatment of complement mediated hemolytic uremic syndrome (cHUS).
Rachel Millner (11522578), Parthak Prodhan (11522584), Richard Blaszak (11522575), Saritha Ranabothu (11522572), Clare C. Brown (9509210), Kristen Rice Moore (11522581)   +5 more
core   +1 more source

Real‐world experience with eculizumab and switching to ravulizumab for generalized myasthenia gravis

Annals of Clinical and Translational Neurology
Objective Eculizumab and ravulizumab are complement protein C5 inhibitors, showing efficacy and tolerability for patients with anti‐acetylcholine receptor‐positive (AChR+) generalized myasthenia gravis (gMG) in phase 3 clinical trials and subsequent ...
Daiki Tokuyasu, Shigeaki Suzuki, Akiyuki Uzawa, Yuriko Nagane, Masayuki Masuda, Shingo Konno, Tomoya Kubota, Makoto Samukawa, Takamichi Sugimoto, Kei Ishizuchi, Munenori Oyama, Manato Yasuda, Hiroyuki Akamine, Yosuke Onishi, Yasushi Suzuki, Naoki Kawaguchi, Naoya Minami, Takashi Kimura, Masanori P. Takahashi, Hiroyuki Murai, Kimiaki Utsugisawa   +20 more
doaj   +1 more source

Analysis of Costs per Responder in US Adults with Paroxysmal Nocturnal Hemoglobinuria with a Suboptimal Response to Prior Eculizumab Treatment

Hematology Reports, 2023
European Society for Blood and Marrow Transplantation (EBMT) hematologic response categories comprehensively assess complement inhibitor responses in patients with paroxysmal nocturnal hemoglobinuria (PNH).
Jesse Fishman, Seri Anderson, Sandra E. Talbird, David Dingli   +3 more
doaj   +1 more source